ImmunityBio's Anktiva Plus BCG Shows Significant Advantages in Bladder Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 27 minutes ago
0mins
Should l Buy IBRX?
Source: stocktwits
- Efficacy Comparison: Anktiva combined with BCG demonstrated a median duration of complete response of 22.1 months in patients with BCG-unresponsive non-muscle invasive bladder cancer, significantly surpassing Nadofaragene's 9.7 months, indicating a potential shift in treatment standards.
- Reduced Side Effects: Patients treated with Anktiva plus BCG experienced a 68% lower risk of treatment-related adverse events compared to TAR-200, which may enhance patient compliance and quality of life due to fewer side effects.
- Enhanced Patent Protection: ImmunityBio secured five U.S. patents covering the use of Anktiva in combination with BCG, with protection lasting until 2035, providing a stronger competitive barrier and market position in bladder cancer treatment.
- Positive Market Sentiment: Despite IBRX shares trading 7% lower, retail sentiment on Stocktwits remains 'bullish', with users expressing that the stock being under $8 is 'incredible', reflecting optimistic expectations regarding the newly released data.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.000
Low
5.00
Averages
7.33
High
9.00
Current: 8.000
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's Anktiva Plus BCG Shows Significant Advantages in Bladder Cancer Treatment
- Efficacy Comparison: Anktiva combined with BCG demonstrated a median duration of complete response of 22.1 months in patients with BCG-unresponsive non-muscle invasive bladder cancer, significantly surpassing Nadofaragene's 9.7 months, indicating a potential shift in treatment standards.
- Reduced Side Effects: Patients treated with Anktiva plus BCG experienced a 68% lower risk of treatment-related adverse events compared to TAR-200, which may enhance patient compliance and quality of life due to fewer side effects.
- Enhanced Patent Protection: ImmunityBio secured five U.S. patents covering the use of Anktiva in combination with BCG, with protection lasting until 2035, providing a stronger competitive barrier and market position in bladder cancer treatment.
- Positive Market Sentiment: Despite IBRX shares trading 7% lower, retail sentiment on Stocktwits remains 'bullish', with users expressing that the stock being under $8 is 'incredible', reflecting optimistic expectations regarding the newly released data.
See More
GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates
- Clinical Advancement: GT Biopharma has advanced three TriKE candidates into the clinic, with GTB-5550 dosing initiated on May 14, 2026, marking a significant milestone in NK cell therapy that is expected to enhance its market competitiveness.
- Innovative Platform: The company's second-generation TriKE platform is described as 10-40 times more potent than the first generation, focusing on activating NK cells through nanobody technology, thereby improving therapeutic efficacy and reducing side effects, further solidifying its position in immuno-oncology.
- Funding Influx: Cumulative funding into NK-focused biotech has exceeded $4.2 billion from 2020 to 2026, indicating strong investment enthusiasm and market potential, with GT Biopharma positioned to benefit from this trend as a key player.
- Market Outlook: North America is expected to capture 44% of the global NK cell therapy market by 2026, and GT Biopharma's clinical trials and financial status provide a solid foundation for growth in this rapidly evolving market.
See More
NAI+BCG Therapy Shows Superior Results in Bladder Cancer Study
- Efficacy Comparison: Patients treated with NAI+BCG were twice as likely to achieve a complete response (CR) compared to those receiving nadofaragene firadenovec-vncg, highlighting NAI+BCG's significant advantage in treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), suggesting it may become a preferred treatment option.
- Response Duration: The median duration of CR for NAI+BCG was 22.1 months, significantly longer than the 9.7 months observed with nadofaragene, with a difference of 12.45 months, emphasizing the long-term efficacy of NAI+BCG and its potential impact on clinical decision-making.
- Surgery Risk Reduction: NAI+BCG reduced the risk of cystectomy by 60% compared to nadofaragene, providing a crucial treatment option for patients seeking bladder preservation, which holds significant clinical implications.
- Safety Advantages: NAI+BCG demonstrated a higher 12-month CR rate than TAR-200 (49.2% vs. 45.9%) and a statistically significant 68% reduction in treatment-related adverse events, indicating that NAI+BCG excels in both safety and efficacy, potentially enhancing its market acceptance.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against ImmunityBio in the Central District of California, targeting investors who purchased the company's securities between January 19, 2026, and March 24, 2026, indicating significant legal risks for the company.
- False Statement Allegations: The lawsuit alleges that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading statements about the company's business, operations, and prospects, which may have caused investor losses.
- Investor Rights Protection: Investors must apply by May 26, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the urgency of legal proceedings and the firm's commitment to protecting investor rights.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, demonstrating its expertise in safeguarding investor interests.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, 2026, allowing potential compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that executives made false or misleading statements during the Class Period, resulting in investor losses when the true information was revealed, indicating significant issues with the company's business and prospects.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of settlements, showcasing its expertise and success in this field.
- Participation Instructions: Investors can join the lawsuit by visiting the designated website or calling the toll-free number, emphasizing the importance of selecting qualified legal counsel to ensure effective representation and support in the litigation.
See More
ImmunityBio Investors Reminder for Class Action Filing
- Lawsuit Background: ImmunityBio faces a class action lawsuit due to misleading statements made by its CEO regarding the drug Anktiva, with the FDA warning that the advertising content is false, resulting in investor losses.
- Stock Price Impact: On March 24, 2026, following the FDA warning, ImmunityBio's stock plummeted by 21.12% to close at $7.42 per share, directly affecting investor confidence and asset value.
- Legal Action: Investors must file a motion by May 26, 2026, to request appointment as lead plaintiff in the class action, alleging the company failed to disclose the true capabilities of Anktiva, misleading investors.
- Investor Rights: Glancy Prongay Wolke & Rotter LLP reminds affected investors to contact the law firm for more information to protect their rights and participate in the lawsuit.
See More
ImmunityBio's Anktiva Plus BCG Shows Significant Advantages in Bladder Cancer Treatment
- Efficacy Comparison: Anktiva combined with BCG demonstrated a median duration of complete response of 22.1 months in patients with BCG-unresponsive non-muscle invasive bladder cancer, significantly surpassing Nadofaragene's 9.7 months, indicating a potential shift in treatment standards.
- Reduced Side Effects: Patients treated with Anktiva plus BCG experienced a 68% lower risk of treatment-related adverse events compared to TAR-200, which may enhance patient compliance and quality of life due to fewer side effects.
- Enhanced Patent Protection: ImmunityBio secured five U.S. patents covering the use of Anktiva in combination with BCG, with protection lasting until 2035, providing a stronger competitive barrier and market position in bladder cancer treatment.
- Positive Market Sentiment: Despite IBRX shares trading 7% lower, retail sentiment on Stocktwits remains 'bullish', with users expressing that the stock being under $8 is 'incredible', reflecting optimistic expectations regarding the newly released data.
See More
GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates
- Clinical Advancement: GT Biopharma has advanced three TriKE candidates into the clinic, with GTB-5550 dosing initiated on May 14, 2026, marking a significant milestone in NK cell therapy that is expected to enhance its market competitiveness.
- Innovative Platform: The company's second-generation TriKE platform is described as 10-40 times more potent than the first generation, focusing on activating NK cells through nanobody technology, thereby improving therapeutic efficacy and reducing side effects, further solidifying its position in immuno-oncology.
- Funding Influx: Cumulative funding into NK-focused biotech has exceeded $4.2 billion from 2020 to 2026, indicating strong investment enthusiasm and market potential, with GT Biopharma positioned to benefit from this trend as a key player.
- Market Outlook: North America is expected to capture 44% of the global NK cell therapy market by 2026, and GT Biopharma's clinical trials and financial status provide a solid foundation for growth in this rapidly evolving market.
See More
NAI+BCG Therapy Shows Superior Results in Bladder Cancer Study
- Efficacy Comparison: Patients treated with NAI+BCG were twice as likely to achieve a complete response (CR) compared to those receiving nadofaragene firadenovec-vncg, highlighting NAI+BCG's significant advantage in treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), suggesting it may become a preferred treatment option.
- Response Duration: The median duration of CR for NAI+BCG was 22.1 months, significantly longer than the 9.7 months observed with nadofaragene, with a difference of 12.45 months, emphasizing the long-term efficacy of NAI+BCG and its potential impact on clinical decision-making.
- Surgery Risk Reduction: NAI+BCG reduced the risk of cystectomy by 60% compared to nadofaragene, providing a crucial treatment option for patients seeking bladder preservation, which holds significant clinical implications.
- Safety Advantages: NAI+BCG demonstrated a higher 12-month CR rate than TAR-200 (49.2% vs. 45.9%) and a statistically significant 68% reduction in treatment-related adverse events, indicating that NAI+BCG excels in both safety and efficacy, potentially enhancing its market acceptance.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against ImmunityBio in the Central District of California, targeting investors who purchased the company's securities between January 19, 2026, and March 24, 2026, indicating significant legal risks for the company.
- False Statement Allegations: The lawsuit alleges that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading statements about the company's business, operations, and prospects, which may have caused investor losses.
- Investor Rights Protection: Investors must apply by May 26, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the urgency of legal proceedings and the firm's commitment to protecting investor rights.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, demonstrating its expertise in safeguarding investor interests.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, 2026, allowing potential compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that executives made false or misleading statements during the Class Period, resulting in investor losses when the true information was revealed, indicating significant issues with the company's business and prospects.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of settlements, showcasing its expertise and success in this field.
- Participation Instructions: Investors can join the lawsuit by visiting the designated website or calling the toll-free number, emphasizing the importance of selecting qualified legal counsel to ensure effective representation and support in the litigation.
See More
ImmunityBio Investors Reminder for Class Action Filing
- Lawsuit Background: ImmunityBio faces a class action lawsuit due to misleading statements made by its CEO regarding the drug Anktiva, with the FDA warning that the advertising content is false, resulting in investor losses.
- Stock Price Impact: On March 24, 2026, following the FDA warning, ImmunityBio's stock plummeted by 21.12% to close at $7.42 per share, directly affecting investor confidence and asset value.
- Legal Action: Investors must file a motion by May 26, 2026, to request appointment as lead plaintiff in the class action, alleging the company failed to disclose the true capabilities of Anktiva, misleading investors.
- Investor Rights: Glancy Prongay Wolke & Rotter LLP reminds affected investors to contact the law firm for more information to protect their rights and participate in the lawsuit.
See More
